trending Market Intelligence /marketintelligence/en/news-insights/trending/cc0lh2wxe_vueh16tmmdtq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Shire wins patent infringement ruling against generics drugmaker

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Shire wins patent infringement ruling against generics drugmaker

Shire PLC said a U.S. district court ruled that Abhai LLC infringed on the Dublin-based drugmaker's patents related to the extended-release version of its attention deficit hyperactivity disorder drug Adderall.

The U.S. District Court of the District of Massachusetts passed the ruling after Shire sued Abhai regarding its abbreviated new drug application to market a generic version of Adderall XR.

The ruling prohibits Abhai from marketing its generic copy until the original patents expire. Further, the court sanctioned Abhai for "litigation misconduct."

The amount Abhai will pay Shire will be decided at a later date.